Spruce Biosciences (SPRB)
(Delayed Data from OTC)
$0.11 USD
0.00 (-0.91%)
Updated Aug 1, 2025 03:36 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SPRB 0.11 0.00(-0.91%)
Will SPRB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SPRB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SPRB
Illumina (ILMN) Q2 Earnings and Revenues Surpass Estimates
Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates
SPRB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
NeoGenomics (NEO) Tops Q4 Earnings Estimates
Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why
Other News for SPRB
Spruce Biosciences to enact 1-for-75 reverse stock split
Spruce Biosciences (SPRB) Advances in Phase 2 Depression Treatment Trial | SPRB Stock News
Spruce, HMNC Brain Health announce first patient dosed in Phase 2 TAMARIND trial
Spruce Biosciences (SPRB) Gains Investor Attention with Significant Interest Surge | SPRB Stock News
Biotech Alert: Searches spiking for these stocks today